Success Metrics

Active Trials
39(58%)

Phase Distribution

Ph early_phase_1
1
1%
Ph phase_1
12
18%
Ph phase_2
46
69%
Ph phase_3
3
4%
Ph not_applicable
3
4%

Phase Distribution

13

Early Stage

46

Mid Stage

3

Late Stage

Phase Distribution65 total trials
Early Phase 1First-in-human
1(1.5%)
Phase 1Safety & dosage
12(18.5%)
Phase 2Efficacy & side effects
46(70.8%)
Phase 3Large-scale testing
3(4.6%)
N/ANon-phased studies
3(4.6%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

39

trials recruiting

Total Trials

67

all time

Status Distribution
Active(55)
Other(12)

Detailed Status

Recruiting33
Not yet recruiting15
unknown12
Active, not recruiting6
Enrolling by invitation1

Development Timeline

Analytics

Development Status

Total Trials
67
Active
39
Success Rate
N/A
Most Advanced
Phase 3

Trials by Phase

Early Phase 11 (1.5%)
Phase 112 (18.5%)
Phase 246 (70.8%)
Phase 33 (4.6%)
N/A3 (4.6%)

Trials by Status

active_not_recruiting69%
recruiting3349%
enrolling_by_invitation11%
unknown1218%
not_yet_recruiting1522%

Recent Activity

Clinical Trials (67)

Showing 20 of 67 trialsScroll for more
NCT06532539Phase 2

Cadonilimab With Chemoradiation for Recurrent and Oligometastatic Endometrial Carcinoma

Recruiting
NCT06187961Phase 2

HAIC, Lenvatinib, and Cadonilimab as Conversion Therapy for Initially Unresectable Hepatocellular Carcinoma

Active Not Recruiting
NCT06143748Phase 2

Combination of Cadonilimab and Chemoradiotherapy in Esophageal Cancer (EC-CRT-006)

Active Not Recruiting
NCT06145308Phase 2

Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing

Recruiting
NCT05824481Phase 2

Study of Cadonilimab (AK104) Plus Lenvatinib in Patients With Advanced Endometrial Cancer

Active Not Recruiting
NCT07450963Phase 2

Cadonilimab Combined With RT in LACC Patients Ineligible for CCRT

Not Yet Recruiting
NCT06530251Phase 1

A Study of AK112 in Patients With Advanced Hepatocellular Carcinoma (HCC)

Recruiting
NCT07446257Early Phase 1

THIO and Cadonilimab in Resectable Hepatocellular Carcinoma

Not Yet Recruiting
NCT06789848Phase 2

Ligufalimab and Cadonilimab in Advanced Liver Cancers

Recruiting
NCT07023315Phase 3

A Phase III Clinical Study of Cadonilimab Plus SOX as Perioperative Treatment for Patients With Resectable G/GEJ Adenocarcinoma

Recruiting
NCT06654011Phase 2

IN10018 With Nab-Paclitaxel and Cadonilimab for Metastatic or Recurrent Gastric-Type Cervical Adenocarcinoma: Phase 2 Trial

Recruiting
NCT05944224Phase 1

A Study to Efficacy and Safety of SPH4336 Monotherapy or in Combination With Cadonilimab in Patients With Advanced Solid Tumors.

Recruiting
NCT07243951Phase 2

Phase II Clinical Study on the Efficacy and Safety of the Combination of Cadonilimab and Capecitabine in Adjuvant Therapy for Combined Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma

Not Yet Recruiting
NCT07245446Phase 2

A Study of Ivonescimab in First-Line ES-SCLC

Recruiting
NCT06367075Phase 2

A Trial of Cadonilimab With Adriamycin in Patients With Advanced Soft Tissue Sarcoma

Recruiting
NCT06494995Phase 2

AK104 and Low-dose Radiation in Recurrent/Metastatic HNSCC After Failure of First-line Systemic Therapy

Recruiting
NCT06367088Phase 2

Cadonilimab Combined With Chemotherapy as First or Second Line Treatment in Recurrent or Metastatic Triple Negative Breast Cancer

Recruiting
NCT06940921Phase 1

SBRT-LDRT-Cadonilimab for Advanced Gastric, Colorectal and Ovarian Cancers With Peritoneal Metastases

Active Not Recruiting
NCT06913218Phase 1

A Study of mRNA Vaccines AK154 Monotherapy or in Combination With AK104/AK112,and Sequential mFOLFIRINOX in Surgically Resected PDAC

Not Yet Recruiting
NCT06715501Not Applicable

Efficacy and Safety of Cadonilimab and Chemoradiotherapy in Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma

Enrolling By Invitation

Drug Details

Intervention Type
DRUG
Total Trials
67